Toronto, Ontario – August 30, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses has released the Company’s unaudited Q22021 condensed interim consolidated financial statements and Quarterly Newsletter (“Newsletter”) which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). The Financial Statements can be found on the Company’s Website at www.theralase.com/financial-filings/ The Newsletter can be found on the Company’s website at www.theralase.com/quarterly-newsletters/ Highlights from the Newsletter: Leadership Transition Effective August 23, 2021, John Trikola assumed the role of Chief Operating Officer (“COO”) and Interim CEO for the Company. John brings over 25 years of technology … Read More

Toronto, Ontario – August 19, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today the departure of its Chief Executive Officer (“CEO”),  Shawn Shirazi effective August 20, 2021. Effective August 23, 2021, John Trikola will assume the role of Chief Operating Officer (“COO”) and Interim CEO for the Company.  John brings over 25 years of technology experience working with companies ranging from startups to global Fortune 500 companies.  Most recently, John was the president of Gardner Ross Corp., where he provided turnaround and restructuring engagements to various companies in the technology, manufacturing, and retail sectors.  In addition to his senior management roles, John currently serves as a Board Director for Waypoint Centre for Mental Health Care and has served on the Board of Directors … Read More

Toronto, Ontario – June 11, 2021, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of innovative Anti-Cancer Therapy (“ACT”) technologies  intended to safely and effectively destroy various cancers, bacteria and viruses, while preserving patient Quality Of Life (“QOL”) announced today the launch of the seventh US-based Clinical Study Site (“CSS”); specifically, the University of Chicago Medicine (“UChicago Medicine”). UChicago Medicine has successfully received Institutional Review Board (“IRB”) approval allowing them to commence enrollment and treatment of patients in Theralase®’s pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). Study II is focused on the enrollment and treatment of approximately 100 to 125 patients, who have been previously diagnosed with Bacillus Calmette Guérin (“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG therapy (“Study II“). The Company has successfully launched five CSSs in Canada … Read More

Toronto, Ontario – May 28, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its unaudited Q12021 condensed interim consolidated financial statements. Financial Highlights: For the three-month periods ended March 31st: Audited Consolidated Statements of Operations             In Canadian Dollars    2021 $ 2020 $ % Change   Revenue       Canada 104,406 111,543 6% United States 20,377 –   Total Revenue 124,783 111,543 12%         Cost of Sales 74,463 99,447 -25% Gross Margin 50,320 12,096 316% Gross Margin as a percentage of sales 60% 89%           Operating Expenses       Selling Expenses 95,780 136,894 -30% Administrative Expenses 418,454 533,329 -22% Research and Development Expenses – CLT Division 54,616 … Read More

Toronto, Ontario – April 28, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2020 financial statements. Financial Highlights: For the years ended December 31st: Audited Consolidated Statements of Operations             In Canadian Dollars     2020 2019 % Change  Revenue       Canada 815,159 835,402 -2% United States 87,923 96,575 -9% International 26,040 32,074 -19% Total Revenue 929,122 964,051 -4%         Cost of Sales 659,442 903,296 -27% Gross Margin 269,680 60,755 344% Gross Margin as a percentage of sales 29% 6% 361%         Operating Expenses       Selling Expenses 447,882 716,343 -37% Administrative Expenses 2,070,261 2,604,808 -21% Research and Development Expenses – CLT Division 230,936 455,617 -49% Research and … Read More

Toronto, Ontario – April 27, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company’s Quarterly Newsletter (“Newsletter”) which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). The Newsletter can be found on the Company’s website at www.theralase.com/quarterly-newsletters/ Highlights from the Newsletter: Clinical Study Sites (“CSS”) 11 CSS’s have been launched in Canada (5) and the US (6) for patient enrollment and treatment for Study II. Patients Treated Study II has enrolled and provided the primary study treatment for 18 patients (including three patients from the Phase Ib study treated at the Therapeutic Dose) for a total of 21 patients. … Read More

Toronto, Ontario – April 9, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses, announced today that it has executed a Collaborative Research Agreement (“CRA”) with the National Microbiology Laboratory, Public Health Agency of Canada (“PHAC”) for the research and development of a Canadian-based SARS-CoV-2 (“COVID-19”) vaccine.  Under the terms of the agreement, Theralase® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase®’s patented PDC and then light activating it with Theralase®’s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This inactivated virus would then be purified and used to … Read More

Toronto, Ontario – March 29, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today the launch of the Theralase® Anti-Cancer Therapy (“ACT”) research centre located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (“UHN”), Toronto. The Li Ka Shing Knowledge Institute of St. Michael’s is home to leading researchers, educators and clinicians — dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice. The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development as it advances towards commercialization with its lead … Read More

Toronto, Ontario – March 25, 2021, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology San Antonio (“USA”) has received site Institutional Review Board (“IRB”) approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the sixth US Clinical Study Site (“CSS”) that has obtained site IRB approval through a central IRB. Theralase is at different stages with additional US clinical study sites that are expected to launch in 2Q21 and 3Q21. Urology San Antonio is the largest urology practice in South Texas with multiple locations offering care … Read More

Toronto, Ontario – February 24, 2021,Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (“UWH”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG“)-Unresponsive Carcinoma In-Situ (“CIS“) or who are intolerant to BCG Therapy (“Study II“). This marks the fifth US clinical site that has successfully obtained site IRB approval through a central IRB. One additional US clinical study site is pending IRB site approval in 1Q2021. The Department of Urology at UWH is a leading academic program offering comprehensive multidisciplinary urologic care in conjunction with innovative research, teaching, … Read More